GSK’s Avandia monthly sales slide to 6 million won

Published: 2010-12-24 06:56:00

Updated: 2010-12-24 06:56:00

GlaxoSmithKline’s embattled diabetes drug Avandia has lost a lot of market ground in the market to competitors as a medicine for type 2 diabetes, even if the Korea Food and Drug Administration (KFDA) ordered doctors to refrain from prescribing it for type-2 diabetes patients last September.

Avandia was widely regarded as one of the most popular diabetes treatments with about 20,000 people ta...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.